Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600055 | 0.84 | ABL1 (0.42) | KDRHDAC1HDAC6SLC6A3ALDH1A1 | |
| SCHEMBL26014402 | 0.84 | ABL1 (0.42) | HDAC1HDAC6HSD17B1HSD17B2SLC6A3 | |
| SCHEMBL10219845 | 0.83 | KDR (0.47) | KDRHDAC6HSD17B1HSD17B2SLC6A3 | |
| SCHEMBL889119 | 0.82 | RAB9A (0.40) | HDAC1HDAC6HSD17B1HSD17B2SLC6A3 | |
| SCHEMBL18760851 | 0.80 | SLC6A3 (0.40) | SLC6A3 | |
| SCHEMBL19625368 | 0.78 | NPC1 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19625372 | 0.77 | ALDH1A1 (0.37) | SLC6A3ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14435919 | 0.76 | AOC3 (0.47) | KDRHDAC1HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL23603567 | 0.76 | NPC1 (0.44) | KDRHDAC1HDAC6HSD17B1HSD17B2 | |
| SCHEMBL15090468 | 0.75 | HSD17B1 (0.50) | KDRHDAC1HDAC6HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2020-05-21 | — | — | US | disclosed |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-11-12 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | KDR 940/4885HDAC1 3629/4885HDAC6 4738/4885 |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | KDR 940/4885HDAC1 3629/4885HDAC6 4738/4885 |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | NEFM, EIF2AK2, IRF3 | KDR 3402/4885HDAC1 1578/4885HDAC6 492/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | KDR 3402/4885HDAC1 1578/4885HDAC6 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.